Aptus Capital Advisors LLC Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Aptus Capital Advisors LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,150 shares of the medical equipment provider’s stock after purchasing an additional 4,543 shares during the period. Aptus Capital Advisors LLC’s holdings in Intuitive Surgical were worth $14,812,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Savvy Advisors Inc. purchased a new position in Intuitive Surgical in the third quarter worth $493,000. Proactive Wealth Strategies LLC purchased a new position in Intuitive Surgical in the third quarter worth $436,000. Sumitomo Mitsui Trust Group Inc. grew its position in Intuitive Surgical by 3.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,638 shares of the medical equipment provider’s stock worth $712,655,000 after acquiring an additional 48,658 shares in the last quarter. Baillie Gifford & Co. boosted its position in Intuitive Surgical by 0.6% during the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock valued at $1,890,676,000 after buying an additional 24,183 shares during the period. Finally, WealthPlan Investment Management LLC boosted its position in Intuitive Surgical by 34.9% during the third quarter. WealthPlan Investment Management LLC now owns 1,983 shares of the medical equipment provider’s stock valued at $974,000 after buying an additional 513 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,006 shares of company stock worth $33,727,766. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on ISRG shares. Truist Financial upped their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Citigroup upped their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Raymond James upped their price objective on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Morgan Stanley upped their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded down $2.82 during trading on Tuesday, reaching $532.93. 197,421 shares of the stock traded hands, compared to its average volume of 1,453,627. Intuitive Surgical, Inc. has a 52-week low of $281.12 and a 52-week high of $542.59. The stock has a 50-day moving average of $494.78 and a two-hundred day moving average of $453.94. The stock has a market cap of $189.82 billion, a P/E ratio of 86.13, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Sell-side analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.